Prevention: what is a programme, what is a package, and what is a policy benefit

One word, three arrangements

Prevention gets sold, offered and legislated for in the same vocabulary, and the three things underneath it work in genuinely different ways.

A population screening programme is a public health activity aimed at a defined group of people who have no symptoms. Someone else decides who is in the group, on evidence about the disease, and the health service goes looking for them. You do not buy it and you do not design it.

A preventive check-up — the chequeo a private policy may offer — is a commercial benefit. Its content is decided by the insurer or the provider, it is offered to whoever holds the policy, and what it contains is a product decision rather than a public health one.

Vaccination is different again: nationally agreed, regionally delivered, and organised around a calendar rather than around a purchase.

Reading the rest of this page with those three kept apart is the whole trick. Nearly every disappointment in this area comes from expecting one of them to behave like another.

What Spain actually runs as a programme

The cancer screening programmes currently carried out in Spain are for breast cancer, colorectal cancer and cervical cancer. They are population programmes, they form part of the common portfolio of care services of the National Health System, and they are carried out in all the autonomous communities and cities.

Three things follow from that, and they are worth holding on to.

The list is short by design. Screening a whole population is only justified where the evidence supports it for that disease, so the absence of a programme for a given condition is a considered position rather than an oversight. A private package offering a longer list of tests is not therefore offering a better version of the same thing; it is offering something else.

Delivery is regional. The programmes are national in the sense of being part of the common portfolio, and regional in how they reach you. Which is why the questions that people most want answered here — at what age am I invited, how often, how does the invitation arrive — are questions for your own autonomous community’s health service. This page does not state them, because the national source states no ages and no intervals, and inventing them would be worse than sending you to the right place.

Entitlement comes first. Being invited depends on being registered with the health service where you live. If that is not yet settled, registering for public healthcare and who can access public healthcare come before anything on this page.

Vaccination, agreed once and delivered locally

Spain works from a common vaccination calendar covering the whole of life, setting out the vaccines recommended by age for the entire population. It is agreed through the Interterritorial Council of the National Health System, the body that harmonises important aspects of health programmes and in which every autonomous community and the Ministry of Health are represented.

For someone arriving from another country, two practical points matter more than the contents of the calendar.

The first is that your own history is now a document you need. Vaccination records do not travel automatically between countries or, sometimes, between regions. Bringing a written record — and having it entered into your health-centre record here — is the difference between continuing a schedule and starting one again.

The second is that the calendar is not only a childhood document. It is organised across life stages, so the question “is there anything I should have had by now?” is a reasonable one to put to a family doctor rather than to an insurer. Travel vaccination sits outside all of this again, in a different service with its own rules.

What a preventive benefit on a policy actually is

Here the honest answer is that it varies completely, which is precisely why it is worth interrogating rather than comparing on the strength of a line in a summary.

A preventive benefit might be a fixed package of tests performed at particular centres. It might be an allowance towards tests a doctor decides on. It might be a benefit included at one cover level and sold separately at another. It might be annual, or less often. It might be available immediately, or after a period. None of that can be read off a brochure, and none of it is stated on this page for any product, because product content belongs in the conditions and in your quote.

What can be said generally is which questions produce a usable answer:

Is it included at this cover level, or bought separately? The first question, because it changes the price comparison entirely.

What is performed, and who decides? A fixed list and a clinical assessment are different products. Ask which this is.

How often, and from when? Frequency, and whether any waiting period applies before the first one.

Where? A benefit deliverable only at centres a long drive away is a benefit you will use once.

And the one that matters most: what happens after an abnormal result? A check that finds something is only useful if the investigation and treatment that follow are covered on ordinary terms. Ask whether follow-up needs authorisation, whether it counts against any annual limit, and whether anything about the finding could later be treated as a condition you now have. That last question is not a trap and the answer is usually unremarkable — but the mechanism it touches is underwriting, which is set out in pre-existing conditions.

Where an answer narrows what you thought you were buying, it is a limiting clause: Spanish contract law requires those to be specially highlighted and specifically accepted in writing, so it should be visible in your documents rather than only in a conversation.

Judging it by the pathway, not the list

The instinct when comparing preventive benefits is to count tests. It is the wrong metric, and it is the one the brochures are written for.

What makes prevention valuable is the pathway: a result that reaches a clinician who acts on it, an abnormal finding that leads to a further test quickly, and a treating relationship in which the finding means something in context. A long list of results delivered without any of that produces anxiety and repeat testing rather than health, and it produces it at the worst possible moment — when you have a number you do not understand and no appointment at which to ask.

So the useful comparison between two policies is not which lists more tests. It is which of them can tell you, in writing, what happens on the day the result comes back abnormal.

Where to read your own answer

Two documents, as always. The general conditions define what the preventive benefit is and state the exclusions attaching to it. Your particular conditions confirm whether it is switched on for the policy you actually hold, at the cover level you actually bought. Which policy document governs sets out how they rank when a summary says something else.

And one document that is not the insurer’s: whatever your regional health service publishes about the screening programmes and the vaccination calendar where you live. That is the source for who is invited and when — and it is free, which is the other reason to check it before buying anything to replace it.